Galmed Pharmaceuticals Ltd. · NASDAQ:GLMD
Galmed Pharmaceuticals — Merger or Acquisition (June 2026)
14 slides from Galmed Pharmaceuticals's merger presentation, Jun 8, 2026
Slide 1: Galmed Colospan: Stoma-Free Future for Patients
GY Galmed colospan Stoma-Free Future for Patients Lal Colospan Video
Slide 2: Forward-Looking Statements
Forward-Looking Statements This Presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are acco
Slide 3: Post-Closing Corporate Structure
Post-Closing Corporate Structure colospan @Galmed Colospan Pharmaceuticals 7 Wholly owned subsidiary focused on innovative GI medical devices, Galmed Pharmaceuticals primarily driving the development and commercialization of the lead asset CG-100. Publicly traded parent company overseeing the strate
Slide 4: Galmed Pharmaceuticals - Key Executives and Board of Directors
Galmed Pharmaceuticals - Key Executives BoardlofiDirectors 30 8 6 Allen Baharaff Doron Cohen Liat Hayardeny Ph.D. David Sidransky M.D. Carol L. Brosgart M.D. Amir Poshinski Shmuel Nir CEO & Director CFO cso Lead Independent Director Director Director Director teva oe (@ GILEAD Wohoenix Colospan: 100
Slide 5: Colorectal Surgery Journey
Colorectal Surgery Journey DIAGNOSIS SURGERY POST-SURGERY 1.9M" worldwide colorectal during surgery, the diseased Anastomotic leak is the No. 4 cancer patients diagnosed per section is removed, and a new problem, leading to increased year anastomosis is created mortality, complications, and costs Ma
Slide 6: Colorectal Surgery is Broken
Colorectal Surgery is Broken STOMA — TODAY’S CLINICAL BURDEN COST/PATIENT STANDARD OF CARE Up to 62% overall complications* 2 24 surgery for closure $ 2 6 K up to Reduced patient QoL “lf we can find a secure way to avoid diverting stoma, this would be the holy grail of colorectal surgery “ Anthony S
Slide 7: CG-100: The New Standard for Colorectal Surgery
CG-100: The New Standard for Colorectal Surgery Replacing diverting stoma with internal bypass: 1 Simpler & faster Maintenance free, i} Easy nonsurgical removal deployment compared no bags, no 24 surgery after 10 days to stoma 7 / CONFIDENTIAL
Slide 8: Addressing a ~$6B Market
Addressing a ~$6B' Market 1M‘ year x ~$6K’/device protective stoma Worldwide candidates ASP US & Canada 201K Western EU 185K CAGR 6.9% (2024- KX - ROW —— 529K Japan, S. Korea & Oceania 111K 1. Based on Colospan's internal assessments 8 7 CONFIDENTIAL 9‘ cq Strategic Market Research ~ Global Colorect
Slide 9: Colospan Achievements
Colospan Achievements “EU-MDR ~ *x* 2017/745 97 Patients treated worldwide Commercial Ready FDA FDA IDE Approval Breakthrough On going pivotal trial in device designation US & EU 90% Of Patients were stoma free 3 Patent Families 16 patents granted (US, EU, China, Japan, India, Brazil, Israel) 9 / CO
Slide 10: Clinical Data Summary - Patients
Clinical Data Summary - 97 Patients’ Patients’ Characteristics 59%) Qarx (63 Mean Age 27 33% eS 90% 7.5cm Receive TT Minimal noe 3 Average Therapy Surgery anastomosis height 97% Colorectal Cancer 7min application time out of 188 min Surgery Safety and Efficacy Data: Colospan vs. Stoma’ 90% Patients
Slide 11: Pivotal Study Design & Status
Pivotal Study Design & Status Study Title Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial Study concept design Randomizing rectal cancer patients into 2 arms: CG-100 vs SOC (stoma) Endpoints Co-primary end
Slide 12: Embraced by Patients & Surgeons
Embraced by Patients & Surgeons | am proud to say that | was the very first patient in Colorado to successfully receive the very first Colospan device , | would like to thank you all for your hard work and pray this gets FDA approved. | was diagnosed with cancer at 29. The bag was one of my top conc
Slide 13: Saving up to $26K per Patient by Avoiding Stoma
Saving up to $26K’ per Patient by Avoiding Stoma Reimbursement foundation established Stoma $2 6 K Reversal . ce = cost reduction D RG = N TA Pp = Ostomy Device fits Eligible for new technology Supplies with existing add-on payment (NTAP) DRG program Rectal Resection OPS ®@ 1% Price Code Dedicated O
Slide 14: Galmed Pharmaceuticals / Colospan Contacts
G? Galmed Pharmaceuticals colospan Contacts: Allen Baharaff ab@galmedpharma.com Boaz Assaf boaz@colospan.com
Galmed Pharmaceuticals — Merger or Acquisition (June 2026) on 6ix